MBL Wealth LLC Raises Holdings in Pfizer Inc. $PFE

MBL Wealth LLC boosted its position in Pfizer Inc. (NYSE:PFE) by 24.4% during the 2nd quarter, Holdings Channel reports. The fund owned 15,764 shares of the biopharmaceutical company’s stock after acquiring an additional 3,094 shares during the quarter. MBL Wealth LLC’s holdings in Pfizer were worth $382,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. GKV Capital Management Co. Inc. purchased a new position in Pfizer in the first quarter valued at approximately $27,000. North Capital Inc. purchased a new position in shares of Pfizer in the 1st quarter valued at $28,000. Bayforest Capital Ltd acquired a new stake in Pfizer during the 1st quarter worth $28,000. Horizon Financial Services LLC purchased a new stake in Pfizer in the first quarter valued at $35,000. Finally, WPG Advisers LLC purchased a new position in shares of Pfizer during the first quarter worth about $35,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Trading Up 1.1%

Shares of PFE opened at $27.37 on Monday. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $30.43. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The firm has a market capitalization of $155.59 billion, a P/E ratio of 14.56, a PEG ratio of 0.88 and a beta of 0.55. The firm’s 50-day moving average is $24.67 and its two-hundred day moving average is $24.12.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. The business had revenue of $14.65 billion for the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company’s revenue was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on PFE shares. Morgan Stanley boosted their target price on Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a report on Wednesday, August 6th. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. UBS Group restated a “neutral” rating and set a $28.00 target price on shares of Pfizer in a research report on Wednesday. Bank of America lifted their target price on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a report on Friday. Finally, Citigroup increased their price target on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $28.41.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.